Regeneron Pharmaceuticals and Sanofi have announced sarilumab met its primary endpoints after 24 weeks in a phase 3 trial of patients with rheumatoid arthritis, according to a company press release.The study comprised 546 patients with rheumatoid arthritis (RA) who were randomly assigned to self-administered, subcutaneous sarilumab at 200 mg or 150 mg every 2 weeks or placebo as an add-on therapy to non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Patients selected for the trial had responded inadequately or were intolerant of prior therapy with tumor necrosis factor-alpha inhibitors (TNF-a) inhibitors, according to the release.
No comments:
Post a Comment